BioCentury
ARTICLE | Company News

Management tracks: Rheos, Aileron

September 6, 2018 10:45 PM UTC

Immunometabolism company Rheos Medicines Inc. (Cambridge, Mass.) hired Sanjay Keswani as CEO. He was SVP and global head of neuroscience, ophthalmology and rare disease for the Pharma Research and Early Development (pRED) group at Roche (SIX:ROG; OTCQX:RHHBY). Keswani succeeds Interim CEO Abbie Celniker, who will remain as Rheos' chairman. She is a partner at Third Rock Ventures.

Rheos launched in March with a $60 million series A round from Third Rock (see "Third Rock Launches Immuno-Metabolism Company Rheos")...